BALAXI PHARMACEUTICALS LIMITED

16%

i e w F i n a n c i a l H i g h l i g h t s Page - 04 Q2 FY22: Quick Overview Revenue higher 16% YoY to INR 702.3 mn EBITDA higher 19% YoY to INR 142 mn PAT higher 19% YoY to INR 120.5 mn Pha

INR 702.3

a n c i a l H i g h l i g h t s Page - 04 Q2 FY22: Quick Overview Revenue higher 16% YoY to INR 702.3 mn EBITDA higher 19% YoY to INR 142 mn PAT higher 19% YoY to INR 120.5 mn Pharmaceuticals Busine

19%

h t s Page - 04 Q2 FY22: Quick Overview Revenue higher 16% YoY to INR 702.3 mn EBITDA higher 19% YoY to INR 142 mn PAT higher 19% YoY to INR 120.5 mn Pharmaceuticals Business contributes 60% o

INR 142

- 04 Q2 FY22: Quick Overview Revenue higher 16% YoY to INR 702.3 mn EBITDA higher 19% YoY to INR 142 mn PAT higher 19% YoY to INR 120.5 mn Pharmaceuticals Business contributes 60% of Revenue Pharma

INR 120.5

evenue higher 16% YoY to INR 702.3 mn EBITDA higher 19% YoY to INR 142 mn PAT higher 19% YoY to INR 120.5 mn Pharmaceuticals Business contributes 60% of Revenue Pharmaceuticals Business contributes 75%

60%

r 19% YoY to INR 142 mn PAT higher 19% YoY to INR 120.5 mn Pharmaceuticals Business contributes 60% of Revenue Pharmaceuticals Business contributes 75% of total gross profit. 28:72 (Branded:Gener

75%

0.5 mn Pharmaceuticals Business contributes 60% of Revenue Pharmaceuticals Business contributes 75% of total gross profit. 28:72 (Branded:Generics) 565 Product Registrations 117 pending approval

16.5%

hlights In INR Mn Revenue (YoY) EBITDA & EBITDA Margin (YoY) PAT & PAT Margin (YoY) 603 702 16.5% 142 20.2% 19% 119 19.7% 121 17.2% 19.3% 101 16.7% 23.0% 22.0% 21.0% 20.0% 19.0% 18.0% 17

20.2%

INR Mn Revenue (YoY) EBITDA & EBITDA Margin (YoY) PAT & PAT Margin (YoY) 603 702 16.5% 142 20.2% 19% 119 19.7% 121 17.2% 19.3% 101 16.7% 23.0% 22.0% 21.0% 20.0% 19.0% 18.0% 17.0% 16.0% 15

19.7%

YoY) EBITDA & EBITDA Margin (YoY) PAT & PAT Margin (YoY) 603 702 16.5% 142 20.2% 19% 119 19.7% 121 17.2% 19.3% 101 16.7% 23.0% 22.0% 21.0% 20.0% 19.0% 18.0% 17.0% 16.0% 15.0% Q2FY21 Q2FY

17.2%

A & EBITDA Margin (YoY) PAT & PAT Margin (YoY) 603 702 16.5% 142 20.2% 19% 119 19.7% 121 17.2% 19.3% 101 16.7% 23.0% 22.0% 21.0% 20.0% 19.0% 18.0% 17.0% 16.0% 15.0% Q2FY21 Q2FY22 Q2FY21

19.3%

TDA Margin (YoY) PAT & PAT Margin (YoY) 603 702 16.5% 142 20.2% 19% 119 19.7% 121 17.2% 19.3% 101 16.7% 23.0% 22.0% 21.0% 20.0% 19.0% 18.0% 17.0% 16.0% 15.0% Q2FY21 Q2FY22 Q2FY21 Q2FY22

“Mission To establish strong portfolios of pharmaceuticals formulations registrations and strong channel networks in each market we target, we are also building a branded consumer products business which complements our pharmaceuticals business and provides us operating leverage on the back of our well-established on-ground infrastructure and commercial relationships.”

“Tapping strong yet fragmented markets, which are difficult to enter Leveraging the strengths of on-ground presence & distribution network Starting with establishing operations in Angola with strong and robust on-ground infrastructure with warehouses, fleet and personnel, we have replicated this model successfully in Guatemala and Dominican Republic and working on replicating this model in other target geographies.”

“» The Company files technical dossier for product registrations in target markets.”

“» With a growing brand penetration in Venezuela, among the top 3 markets by size in Latin America, we now aim to create in-roads in this region as well.”

“Asset-Light Production Once identified, we develop our products by working with reliable outsourcing partners for high quality and reliability and registering these products within our respective multiple target markets.”

“It has also set its eyes on entering additional markets in Africa (similar characteristics to Angola) and Latin America in the medium term.”

“• Guatemala is the biggest pharmaceuticals market in Central America and expected to grow at 8.1% CAGR to reach US$1.5 billion by 2021.”

Balaxi Pharmaceuticals

4

Pharma Product Portfolio

4

Pharmaceuticals Business

4

Strong Management

3

Our Genesis

2

How We Operate

2

Investing In Balaxi

2

Strong Governance

2

Key Criteria for Market Selection

1

New Geographies

1

Balaxi Pharmaceuticals

Bridging the supply chain gap in frontier markets B A L A X I P H A R M A C E U T I C A LS L I M I T E D We are a branded IPR-based pharmaceuticals Company focusing on frontier markets, with a vast and growing portfolio of drugs across multiple therapeutic segments. Vision To be amongst top two generic pharmaceuticals players in multiple global frontier markets, giving us scale, market homogeneity, healthy margins and quality growth where value and volume are both established in a balanced way. Mission To establish strong portfolios of pharmaceuticals formulations registrations and strong channel networks in each market we target, we are also building a branded consumer products business which complements our pharmaceuticals business and provides us operating leverage on the back of our well-established on-ground infrastructure and commercial relationships. Page - 12

Balaxi Pharmaceuticals

Bridging the supply chain gap in the frontier markets B A L A X I P H A R M A C E U T I C A LS L I M I T E D Our value system is the foundation for transparency and strong corporate governance. While we create value for shareowners, we work ethically and honestly to positively impact all our stakeholders sustainably. Values » Customer Centricity » Quality Products » Professional Approach » Best-in-Class Business Practices Purpose To bring high-quality every-day medicines within the reach of populations in promising frontier markets, thus creating sustainable value for our stakeholders. Page - 13

Balaxi Pharmaceuticals

Global Presence With Localisation B A L A X I P H A R M A C E U T I C A LS L I M I T E D A growing pharmaceuticals company with on-ground presence in markets within Africa, Caribbean Islands & Latin America Headquartered in Hyderabad, India, we are an IPR-driven asset-light pharma company with a distinct produce, stock & sell model, supplying branded and generic medicines in chosen markets. Tapping strong yet fragmented markets, which are difficult to enter Leveraging the strengths of on-ground presence & distribution network Starting with establishing operations in Angola with strong and robust on-ground infrastructure with warehouses, fleet and personnel, we have replicated this model successfully in Guatemala and Dominican Republic and working on replicating this model in other target geographies. Balaxi Pharmaceuticals Limited Amongst the top two generic pharma players in our chosen markets, successfully leveraging our infrastructure and relationships to exploit opportunities in br

Our Genesis

The Company’s Evolution B A L A X I P H A R M A C E U T I C A LS L I M I T E D Pre 2017 » The Company was listed on NSE in 2015 as ‘The Anandam Rubber Company Ltd’ 2020-2021 » The Company received an approval for change of name from ‘Balaxi Ventures Ltd.’ to ‘Balaxi Pharmaceuticals Ltd’, in line with the predominant focus on the Pharma vertical. » The Company began progressively consolidating various well- established businesses of the Balaxi Group. » Balaxi now has in its fold a rich portfolio of 564 pharmaceuticals product registrations, strong distribution strength of 40 warehouses and a fleet of owned vehicles across 5 countries. 2017-2019 » In March, 2017, the Company was taken over by Balaxi Group, a prominent pharmaceuticals player in Angola. » Subsequently, the name of the Company was changed to ‘Balaxi Ventures Limited’. » By 2019, Balaxi Group had extended its pharmaceuticals business presence to, Guatemala, and Dominican Republic as well. Page - 15

Our Genesis

Balaxi Group’s Journey 2003-07 2008-10 2011-13 2014-16 2017-19 » Commenced Pharmaceuticals business by supplying white labelled products to customers in Africa. » Sourcing was from WHO GMP certified plants based in India. » Created front-end presence for its Pharmaceuticals business by setting up 1st wholesale depot in Angola in 2008. » Started sourcing pharmaceuticals from WHO GMP certified manufacturers in China by setting up an office in China in 2011. » Opened first wholesale depot for its ancillary business in Angola. » In 2014, the Group expanded its pharma business in Angola by setting up its 12th wholesale depot and a central distribution warehouse. » Made in-roads in the Dominican Republic pharmaceuticals market, submitted technical dossiers for securing product registrations and opened a central distribution warehouse. » Setup central distribution warehouse in Guatemala marking the entry of BALAXI into its third geography. » Further unlocked the potential of vast infrastructu

How We Operate

Our Approach For Creating Value B A L A X I P H A R M A C E U T I C A LS L I M I T E D 1 Intellectual Property Research 2 3 4 5 6 Product Registrations Asset-Light Production Geographical Footprint Focus on Brand Equity » Balaxi undertakes » 564 valid pharmaceuticals product registrations. » The Company aims to double its portfolio of product registrations over the next two years. proprietary market research and assesses the demand for various products. » The Company files technical dossier for product registrations in target markets. » A well-established expert regulatory team, which carefully monitors the registration process at every stage. » Manufacturing is outsourced to WHO GMP certified contract manufacturers based in India, China and Portugal. » Well-established in the existing markets of Angola, Guatemala, Honduras and Dominican Republic. » Poised to expand footprint in El Salvador, Nicaragua, Mozambique and Central African Republic (CAR). » Increased share of branded products